These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 1386590)

  • 1. In vitro activity of clarithromycin and its 14-hydroxy-metabolite against 203 strains of Haemophilus influenzae.
    Bergeron MG; Bernier M; L'Ecuyer J
    Infection; 1992; 20(3):164-7. PubMed ID: 1386590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-vitro activity of clarithromycin combined with its 14-hydroxy metabolite A-62671 against Haemophilus influenzae.
    Olsson-Liljequist B; Hoffman BM
    J Antimicrob Chemother; 1991 Feb; 27 Suppl A():11-7. PubMed ID: 1827097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans.
    Hardy DJ; Swanson RN; Rode RA; Marsh K; Shipkowitz NL; Clement JJ
    Antimicrob Agents Chemother; 1990 Jul; 34(7):1407-13. PubMed ID: 2143642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The activity of clarithromycin and its 14-hydroxy metabolite against Haemophilus influenzae, determined by in-vitro and serum bactericidal tests.
    Dabernat H; Delmas C; Seguy M; Fourtillan JB; Girault J; Lareng MB
    J Antimicrob Chemother; 1991 Feb; 27 Suppl A():19-30. PubMed ID: 1827099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individual and combined activities of clarithromycin and its 14-hydroxy metabolite in a murine model of Haemophilus influenzae infection.
    Vallée E; Azoulay-Dupuis E; Swanson R; Bergogne-Bérézin E; Pocidalo JJ
    J Antimicrob Chemother; 1991 Feb; 27 Suppl A():31-41. PubMed ID: 1827100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of telithromycin against Haemophilus influenzae at epithelial lining fluid concentrations.
    De Vecchi E; Nicola L; Larosa M; Drago L
    BMC Microbiol; 2008 Jan; 8():23. PubMed ID: 18230154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of clarithromycin and its principal human metabolite against Haemophilus influenzae.
    Jorgensen JH; Maher LA; Howell AW
    Antimicrob Agents Chemother; 1991 Jul; 35(7):1524-6. PubMed ID: 1834012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The in-vitro and disc susceptibility testing of clarithromycin and its 14-hydroxy metabolite.
    Logan MN; Ashby JP; Andrews JM; Wise R
    J Antimicrob Chemother; 1991 Feb; 27(2):161-70. PubMed ID: 1829073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-vitro cidal activity of clarithromycin and its 14-hydroxy metabolite (A-62671) against Haemophilus influenzae.
    Powell M; Chen HY; Weinhardt B; Williams JD
    J Antimicrob Chemother; 1991 May; 27(5):694-6. PubMed ID: 1832146
    [No Abstract]   [Full Text] [Related]  

  • 10. Clarithromycin in vitro activity enhanced by its major metabolite, 14-hydroxyclarithromycin.
    Hoover WW; Barrett MS; Jones RN
    Diagn Microbiol Infect Dis; 1992; 15(3):259-66. PubMed ID: 1533827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibility of Haemophilus influenzae to clarithromycin alone and in combination with its 14-hydroxy metabolite.
    Barry AL; Fuchs PC; Pfaller MA
    Eur J Clin Microbiol Infect Dis; 1991 Dec; 10(12):1080-1. PubMed ID: 1839381
    [No Abstract]   [Full Text] [Related]  

  • 12. Bactericidal activity of clarithromycin and its 14-hydroxy metabolite against Haemophilus influenzae and streptococcal pathogens.
    Gu JW; Scully BE; Neu HC
    J Clin Pharmacol; 1991 Dec; 31(12):1146-50. PubMed ID: 1837032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variability of clarithromycin and erythromycin susceptibility tests with Haemophilus influenzae in four different broth media and correlation with the standard disk diffusion test.
    Barry AL; Fernandes PB; Jorgensen JH; Thornsberry C; Hardy DJ; Jones RN
    J Clin Microbiol; 1988 Nov; 26(11):2415-20. PubMed ID: 2976773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of antibiotic-resistant Streptococcus pneumoniae and beta-lactamase-positive Haemophilus influenzae in clinical isolates from patients with otitis media.
    McLinn S; Williams D
    Pediatr Infect Dis J; 1996 Sep; 15(9 Suppl):S3-9. PubMed ID: 8878239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of variations in test methods on susceptibility of Haemophilus influenzae to ampicillin, azithromycin, clarithromycin, and telithromycin.
    Fuchs PC; Barry AL; Brown SD
    J Clin Microbiol; 2001 Jan; 39(1):43-6. PubMed ID: 11136745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of antimicrobial activities of clarithromycin and 14-hydroxyclarithromycin against three strains of Haemophilus influenzae by using an in vitro pharmacodynamic model.
    Walker KJ; Larsson AJ; Zabinski RA; Rotschafer JC
    Antimicrob Agents Chemother; 1994 Sep; 38(9):2003-7. PubMed ID: 7811010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective efficacy of clarithromycin and its 14-hydroxy metabolite against Haemophilus influenzae in a murine septicaemia model.
    Chen HY; Maskell JP; Powell M
    J Antimicrob Chemother; 1992 May; 29(5):602-3. PubMed ID: 1385590
    [No Abstract]   [Full Text] [Related]  

  • 18. Increasing prevalence of ampicillin- resistant, non-beta-lactamase-producing strains of Haemophilus influenzae in children in Japan.
    Seki H; Kasahara Y; Ohta K; Saikawa Y; Sumita R; Yachie A; Fujita S; Koizumi S
    Chemotherapy; 1999; 45(1):15-21. PubMed ID: 9876205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the in-vitro activity of clarithromycin, a new macrolide antibiotic, with erythromycin and other oral agents.
    King A; Phillips I
    J Hosp Infect; 1991 Sep; 19 Suppl A():3-9. PubMed ID: 1684981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population genetics and antibiotic susceptibility of invasive Haemophilus influenzae in Manitoba, Canada, from 2000 to 2006.
    Sill ML; Law DK; Zhou J; Skinner S; Wylie J; Tsang RS
    FEMS Immunol Med Microbiol; 2007 Nov; 51(2):270-6. PubMed ID: 17922774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.